Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Mar 31, 2025 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 4.79%34.29B | 4.62%32.73B | 6.40%8.63B | 1.82%8.21B | 9.71%8.53B | 0.34%7.36B | 6.22%31.28B | -1.45%8.11B | 12.79%8.06B | 8.47%7.78B |
| Cost of revenue | 4.63%28.43B | 5.07%27.17B | 6.51%7.32B | 4.05%6.76B | 8.83%6.98B | 0.59%6.11B | 6.21%25.86B | 4.82%6.87B | 10.69%6.5B | 4.43%6.41B |
| Gross profit | 5.56%5.87B | 2.47%5.56B | 5.80%1.31B | -7.51%1.44B | 14.02%1.55B | -0.95%1.25B | 6.27%5.42B | -25.98%1.24B | 22.58%1.56B | 32.36%1.36B |
| Operating expense | 3.66%4.7B | 1.07%4.53B | 0.89%1.13B | 3.79%1.12B | 0.35%1.13B | -0.61%1.14B | 3.01%4.48B | -4.75%1.12B | -0.55%1.08B | 8.68%1.13B |
| Staff costs | -1.06%1.59B | 1.39%1.61B | ---- | ---- | ---- | ---- | 1.86%1.59B | ---- | ---- | ---- |
| Selling and administrative expenses | 10.26%1.09B | -1.70%984M | ---- | ---- | ---- | ---- | -0.69%1B | ---- | ---- | ---- |
| -Selling and marketing expense | 12.00%952M | -3.19%850M | ---- | ---- | ---- | ---- | -5.08%878M | ---- | ---- | ---- |
| -General and administrative expense | -0.75%133M | 8.94%134M | ---- | ---- | ---- | ---- | 48.19%123M | ---- | ---- | ---- |
| Research and development costs | 11.93%563M | 14.58%503M | ---- | ---- | ---- | ---- | 7.07%439M | ---- | ---- | ---- |
| Other operating expenses | 1.53%1.46B | -1.44%1.44B | ---- | ---- | ---- | ---- | 5.81%1.46B | ---- | ---- | ---- |
| Operating profit | 13.94%1.17B | 9.15%1.03B | 52.10%181M | -33.26%317M | 79.57%422M | -4.50%106M | 25.17%940M | -76.15%119M | 160.99%475M | 3,037.50%235M |
| Net non-operating interest income (expenses) | -650.00%-30M | -500.00%-4M | 0.00%-2M | -150.00%-1M | -3M | 100.00%2M | 150.00%1M | -300.00%-2M | 300.00%2M | 0 |
| Non-operating interest income | -8.33%55M | 11.11%60M | 25.00%15M | 0.00%16M | 16.67%14M | 7.14%15M | 12.50%54M | -7.69%12M | 23.08%16M | 20.00%12M |
| Non-operating interest expense | 32.81%85M | 20.75%64M | 21.43%17M | 21.43%17M | 41.67%17M | 0.00%13M | 6.00%53M | 16.67%14M | 0.00%14M | -7.69%12M |
| Net investment income | 0.00%59M | 51.28%59M | 0 | 183.33%17M | 50.00%3M | 18.18%39M | -9.30%39M | -2M | 0.00%6M | 100.00%2M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | 166M | 0 | 0 | 0 | 123M | 0 | 0 | |||
| Income from associates and other participating interests | 308.82%71M | -142.50%-34M | 250.00%3M | -177.42%-24M | -122.22%-4M | -127.27%-9M | 60.00%80M | -111.11%-2M | 82.35%31M | 28.57%18M |
| Special income (charges) | -183.63%-143M | 757.69%171M | 3,220.00%156M | -500.00%-4M | 866.67%23M | 78.95%-4M | 35.00%-26M | 54.55%-5M | 133.33%1M | 75.00%-3M |
| Less:Other special charges | 183.63%143M | -784.00%-171M | -4,000.00%-156M | 500.00%4M | -866.67%-23M | -78.95%4M | -21.88%25M | 33.33%4M | -133.33%-1M | -75.00%3M |
| Less:Write off | ---- | --0 | ---- | ---- | ---- | ---- | -87.50%1M | ---- | ---- | ---- |
| Other non-operating income (expenses) | 40.00%-9M | -250.00%-15M | -377.78%-25M | 154.17%13M | 30.00%-7M | -88.57%4M | -85.29%10M | 800.00%9M | -84.62%-24M | -132.26%-10M |
| Income before tax | 7.01%1.28B | 2.83%1.2B | 174.34%310M | -35.44%317M | 18.21%435M | -29.38%137M | 34.64%1.17B | -77.58%113M | 162.57%491M | 1,433.33%368M |
| Income tax | -15.02%249M | -12.28%293M | 300.00%152M | -86.09%21M | 17.78%106M | -74.55%14M | 25.09%334M | -75.00%38M | 122.06%151M | 2,350.00%90M |
| Net income | 14.13%1.03B | 8.89%906M | 110.67%158M | -12.90%297M | 18.35%329M | -11.59%122M | 38.90%832M | -78.75%75M | 188.98%341M | 892.86%278M |
| Net income continuous operations | 14.13%1.03B | 8.89%906M | 110.67%158M | -12.94%296M | 18.35%329M | -11.51%123M | 38.90%832M | -78.69%75M | 185.71%340M | 892.86%278M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 14.13%1.03B | 8.89%906M | 110.67%158M | -12.90%297M | 18.35%329M | -11.59%122M | 38.90%832M | -78.75%75M | 188.98%341M | 892.86%278M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 14.13%1.03B | 8.89%906M | 110.67%158M | -12.90%297M | 18.35%329M | -11.59%122M | 38.90%832M | -78.75%75M | 188.98%341M | 892.86%278M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 14.17%175.04 | 8.84%153.32 | 108.21%26.63 | -12.65%50.28 | 18.32%55.67 | -11.63%20.74 | 38.54%140.87 | -78.64%12.79 | 188.81%57.56 | 860.20%47.05 |
| Diluted earnings per share | 14.17%175.04 | 8.84%153.32 | 109.88%26.63 | -12.70%50.2509 | 18.37%55.659 | -11.63%20.74 | 38.54%140.87 | -78.75%12.6882 | 188.81%57.56 | 889.83%47.023 |
| Dividend per share | 20.00%60 | 11.11%50 | 0.00%25 | 0 | 25.00%25 | 0 | 28.57%45 | -28.57%25 | 0 | 20 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |